These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 8644760

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Electrocardiographic findings in Ethiopians on pentavalent antimony therapy for visceral leishmaniasis.
    Berhe N, Abraham Y, Hailu A, Ali A, Mengistu G, Tsige K, Abebe Y.
    East Afr Med J; 2001 Nov; 78(11):608-10. PubMed ID: 12219968
    [Abstract] [Full Text] [Related]

  • 3. Visceral leishmaniasis in HIV-1-infected individuals: a common opportunistic infection in Spain?
    Medrano FJ, Hernández-Quero J, Jiménez E, Pineda JA, Rivero A, Sánchez-Quijano A, Velez ID, Viciana P, Castillo R, Reyes MJ.
    AIDS; 1992 Dec; 6(12):1499-503. PubMed ID: 1362880
    [Abstract] [Full Text] [Related]

  • 4. Assessment of allopurinol plus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV.
    Laguna F, López-Vélez R, Soriano V, Montilla P, Alvar J, González-Lahoz JM.
    J Infect; 1994 May; 28(3):255-9. PubMed ID: 8089514
    [Abstract] [Full Text] [Related]

  • 5. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients.
    Delgado J, Macías J, Pineda JA, Corzo JE, González-Moreno MP, de la Rosa R, Sánchez-Quijano A, Leal M, Lissen E.
    Am J Trop Med Hyg; 1999 Nov; 61(5):766-9. PubMed ID: 10586909
    [Abstract] [Full Text] [Related]

  • 6. Relapse in Ethiopian visceral leishmaniasis (VL) patients after therapy with pentavalent antimonials: a ten year observation.
    Berhe N, Ali A, Hailu A, Yeneneh H.
    Acta Trop; 1994 Jun; 57(1):83-90. PubMed ID: 7942358
    [Abstract] [Full Text] [Related]

  • 7. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.
    Laguna F, López-Vélez R, Pulido F, Salas A, Torre-Cisneros J, Torres E, Medrano FJ, Sanz J, Picó G, Gómez-Rodrigo J, Pasquau J, Alvar J.
    AIDS; 1999 Jun 18; 13(9):1063-9. PubMed ID: 10397536
    [Abstract] [Full Text] [Related]

  • 8. Effects of antimonial therapy for canine leishmaniasis on antibody titer.
    Amusategui I, Sainz A, Tesouro MA.
    Ann N Y Acad Sci; 1998 Jun 29; 849():444-6. PubMed ID: 9668509
    [No Abstract] [Full Text] [Related]

  • 9. New delivery strategies for the old pentavalent antimonial drugs.
    Frézard F, Demicheli C.
    Expert Opin Drug Deliv; 2010 Dec 29; 7(12):1343-58. PubMed ID: 21029028
    [Abstract] [Full Text] [Related]

  • 10. Chemotherapy of leishmaniasis in India.
    Thakur CP.
    Indian J Pediatr; 1987 Dec 29; 54(1):7-10. PubMed ID: 3030933
    [No Abstract] [Full Text] [Related]

  • 11. Low dosage combination of meglumine antimoniate plus allopurinol as first choice treatment of infantile visceral leishmaniasis in Italy.
    di Martino L, Mantovani MP, Gradoni L, Gramiccia M, Guandalini S.
    Trans R Soc Trop Med Hyg; 1990 Dec 29; 84(4):534-5. PubMed ID: 2091347
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Epidemiologic surveillance of visceral leishmaniasis in Sicily, Italy.
    Cascio A, Gradoni L, Scarlata F, Gramiccia M, Giordano S, Russo R, Scalone A, Camma C, Titone L.
    Am J Trop Med Hyg; 1997 Jul 29; 57(1):75-8. PubMed ID: 9242323
    [Abstract] [Full Text] [Related]

  • 15. Evolution of serum albumin/globulin ratio after antimonial therapy in canine leishmaniasis.
    Amusategui I, Sainz A, Tesouro MA.
    Ann N Y Acad Sci; 1998 Jun 29; 849():447-9. PubMed ID: 9668510
    [No Abstract] [Full Text] [Related]

  • 16. [Treatment of infantile visceral leishmaniasis].
    Minodier P, Faraut-Gambarelli F, Piarroux R, Gire C, Garnier JM, Dumon H.
    Arch Pediatr; 1999 Jan 29; 6(1):59-66. PubMed ID: 9974099
    [Abstract] [Full Text] [Related]

  • 17. [Treatment of visceral leishmaniasis in children].
    Minodier P, Noël G, Blanc P, Uters M, Retornaz K, Garnier JM.
    Med Trop (Mars); 2007 Feb 29; 67(1):73-8. PubMed ID: 17506279
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
    Molina I, Falcó V, Crespo M, Riera C, Ribera E, Curran A, Carrio J, Diaz M, Villar del Saz S, Fisa R, López-Chejade P, Ocaña I, Pahissa A.
    J Antimicrob Chemother; 2007 Oct 29; 60(4):837-42. PubMed ID: 17684055
    [Abstract] [Full Text] [Related]

  • 19. Species-specific antimonial sensitivity in Leishmania is driven by post-transcriptional regulation of AQP1.
    Mandal G, Mandal S, Sharma M, Charret KS, Papadopoulou B, Bhattacharjee H, Mukhopadhyay R.
    PLoS Negl Trop Dis; 2015 Feb 29; 9(2):e0003500. PubMed ID: 25714343
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.